Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.62
Bid: 3.32
Ask: 3.86
Change: 0.12 (3.46%)
Spread: 0.54 (16.265%)
Open: 3.56
High: 3.62
Low: 3.44
Prev. Close: 3.47
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First US patent issues for PREtec peptide products

23 Jan 2020 07:00

RNS Number : 6559A
Plant Health Care PLC
23 January 2020
 

23 January 2020

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

First US patent issues for PREtec peptide products

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets with a strong track record of successful commercialisation of new technologies, is pleased to announce the granting of the first US patent on its novel PREtec peptide technology.

 

Highlights:

- Plant Health Care has filed more than 50 patent applications worldwide for its PREtec peptide technology since 2012

- The first of these patents has now been granted by the US Patent and Trademark Office (USPTO)

- The patent provides protection for a series of PREtec peptides in a wide range of agricultural uses

- Additional patents are expected to be granted over the coming months

- The Company is planning to commercialise PREtec peptides into market opportunities worth more than $5bn

 

Plant Health Care is developing novel peptide products from the PREtec (Plant Response Elicitor) platform. These products act as 'vaccines for plants'; they stimulate the plant to defend itself from stress, such as disease and drought, leading to better quality and higher yield at harvest. Derived from natural proteins, PREtec peptides are a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practices. The Company is initially targeting market opportunities worth more than $5bn.

US patent No. 10,470,461, issued November 12, 2019, claims a large number of unique response elicitor peptides, as well as their use in combination with other agricultural products to enhance disease resistance, improve plant growth, and impart tolerance to both biotic stresses and abiotic stresses such as heat, drought, and excess soil salinity.

 

Zhongmin Wei, Ph.D., Chief Scientific Officer for Plant Health Care and inventor of the PREtec technology said, "I am pleased that the USPTO has recognized the patentability of the response elicitor peptide sequences and their use for agricultural production. This is the first of a series of patents that we expect will issue shortly. Plant Health Care is carving out a dominant patent position around the use of response elicitor peptides in agriculture."

 

Chris Richards, CEO of Plant Health Care, said, "Receiving this patent is another significant milestone in our path to bringing PREtec peptides to commercial sales. Alongside our recently announced progress at scaling up manufacture of our lead peptide, PHC279, and the exciting results shown for the control of Asian Soybean Rust (ASR) in Brazil, this further boosts our confidence about the commercial potential for PREtec based products. We are preparing to launch this novel technology directly to markets in USA, Brazil and other countries, once regulatory permits are in place."

 

 

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO Tel: +1 919 926 1600

Jeff Tweedy, COO Tel: +1 919 926 1600

Arden Partners plc - Nomad and Broker

John Llewellyn-Lloyd / Dan Gee-Summons (Corporate Finance) Tel: +44 (0) 20 7614 5900

Fraser Marshall (Equity Sales)

Company website: www.planthealthcare.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAGZGZMGZFGGZZ
Date   Source Headline
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.